The end of the word is here: In re Alsabah

March 24th, 2017

The oral argument of the day is In re Alsabah.  I hope the appellant requests re-hearing in this rule 36 judgment.  The outcome seems inconsistent with the Federal Circuit’s statement in In re Smith:

That is not to say that all inventions in the gaming arts would be foreclosed from patent protection under § 101. We could envisage, for example, claims directed to conducting a game using a new or original deck of cards potentially surviving step two of Alice. The Government acknowledged as much during oral argument. See Oral Argument at 14:59-15:31, available at http://oralarguments.cafc.uscourts.gov/default.aspx?fl=2015-1664.mp3.

In re Smith, 815 F.3d 816, 819 (Fed. Cir. 2016).

From what I could discern from the oral argument, it is hard to believe that the claim as a whole recites routine, conventional, and well-understood subject matter, under Step 2 of Alice or Step 2B of the PTO guidelines.

The oral argument is available [here].

The Rule 36 judgment is available [here].

Patents as property rights — mining patents, that is

March 24th, 2017

The Federal Circuit issued a different kind of patent opinion last week — a decision relating to patents on mining claims.  Apparently, the patents that the US government issues for mining claims are considered property rights in the full sense:

Once established, a mining claimant receives “a `patent,’ that is, an official document issued by the United States attesting that fee title to the land is in the private owner.” Kunkes v. United States, 78 F.3d 1549, 1551 (Fed. Cir. 1996). A patented mining claim is “a property right in the full sense.” Union Oil Co. v. Smith,249 U.S. 337, 349 (1919).

REOFORCE, INC. v. US, No. 2015-5084 (Fed. Cir. Mar. 17, 2017)(slip op. at page 4).

The court’s opinion in REOFORCE, INC. v. US, No. 2015-5084 (Fed. Cir. Mar. 17, 2017) is available [here] and [here].

Oral Argument of the day: Trader Joe’s v. Hallatt

March 22nd, 2017

With the extraterritoriality issues being argued today in the Lexmark patent case, I am reminded of the extraterritoriality trademark case of Trader Joe’s v. Hallatt from the Ninth Circuit.  The Ninth Circuit’s 2016 opinion is available [here].

Oral Argument of the Day: CRST Van Expedited, Inc. v. EEOC

March 20th, 2017

The oral argument of the day comes from a Supreme Court case argued last term, CRST Van Expedited, Inc. v. EEOC, 136 S. Ct. 1642, 578 U.S., 194 L. Ed. 2d 707 (2016).  The Court held that a favorable ruling on the merits is not a necessary predicate to find that a defendant has prevailed.

The oral argument is available [here].

The Court’s opinion is available [here].

This case came up in the Federal Circuit oral argument of Advanced Video Technologies v. HTC et al.

Quote for the day

March 14th, 2017
The quote for the day comes from the Supreme Court’s recent decision in LIFE TECHNOLOGIES CORPORATION v. PROMEGA CORPORATION, No. 14-1538 (U.S. Feb. 22, 2017).  In that decision the Court was attempting to discern whether Section 271(f)(1)’s phrase “substantial portion” refers to a qualitative or a quantitative analysis.  The Court said:

As a more general matter, moreover, we cannot accept Promega’s suggestion that the Court adopt a different analytical framework entirely—one that accounts for both the quantitative and qualitative aspects of the components. Promega reads §271(f)(1) to mean that the answer to whether a given portion of the components is “substantial” depends not only on the number of components involved but also on their qualitative importance to the invention overall. At first blush, there is some appeal to the idea that, in close cases, a subjective analysis of the qualitative importance of a component may help determine whether it is a “substantial portion” of the components of a patent. But, for the reasons discussed above, the statute’s structure provides little support for a qualitative interpretation of the term.

Nor would considering the qualitative importance of a component necessarily help resolve close cases. To the contrary, it might just as easily complicate the factfinder’s review. Surely a great many components of an invention (if not every component) are important. Few inventions, including the one at issue here, would function at all without any one of their components. Indeed, Promega has not identified any component covered by the Tautz patent that would not satisfy Promega’s “importance” litmus test. How are courts—or, for that matter, market participants attempting to avoid liability—to determine the relative importance of the components of an invention? Neither Promega nor the Federal Circuit offers an easy way to make this decision. Accordingly, we conclude that a quantitative interpretation hews most closely to the text of the statute and provides an administrable construction.

LIFE TECHNOLOGIES CORPORATION v. PROMEGA CORPORATION, No. 14-1538 (U.S. Feb. 22, 2017)(emphasis added).

Isn’t it interesting how outside of the context of §101, all claim limitations take on a renewed sense of importance.  Indeed, the Court states that “a great many components of an invention (if not every component) are important.  Few inventions . . . would function at all without any one of their components.”  There is no wave of the hand to dismiss mere pre-solution activity or post-solution activity.  Rather, as it should be, every component of a claim is once again deemed important.  How refreshing.

Moreover, the Court noted how difficult it could be for a factfinder to assess the qualitative importance of a particular claim element.  This “qualitative importance” language sounds a little bit like the “significantly more” language of Mayo.  Interesting that the Court had a problem with “qualitative importance” being too difficult for a factfinder to apply, yet left the patent bar twisting in the wind with its “significantly more” test.

It will be interesting to see if this quote from Life Technologies makes its way into any §101 opinions of the Federal Circuit.  After all, it is the most recent pronouncement from the Supreme Court that all claim limitations are important.


De novo review

March 9th, 2017

If you were an appellate judge, I imagine that you would prefer to review a lot of matters as “issues of law.”  The great thing about issues of law is that issues of law make the appellate court the final arbiter of a determination.  As you know, issues of law are reviewed de novo.  Issues of fact are reviewed with some level of deference to the factfinder.

In the previous post, I explained that there are several issues percolating at the Federal Circuit with respect to §101 that have not yet been resolved as issues of law or issues of fact.  Perhaps the prospect of giving up de novo review has something to do with that delay.

Retired Chief Judge Rader was a staunch critic of the doctrine of claim vitiation.  He explained that the tests for vitiation and equivalents are coterminous.  The only difference was that the doctrine of claim vitiation was an issue of law (reviewed de novo) while the doctrine of equivalents was an issue of fact (not reviewed de novo).  Therefore, one could assert the doctrine of claim vitiation for purposes of summary judgment, since there could be no fact issue to dispute.  You can hear him explain this in the 2007 oral argument of Wleklinski v. Targus [Listen]. See also his “Additional views” in the Nystrom v. Trex case.

While Judge Rader does not mention it, the adoption of de novo review for the doctrine of claim vitiation also made the appellate judges the final arbiters of a doctrine of claim vitiation analysis.  They do not need to defer to any factfinder.

We will have to wait and see how the Federal Circuit resolves the §101 issues.

“We’re talking about . . . evidence”

March 2nd, 2017

It is no secret that the Supreme Court has made a dog’s breakfast out of 35 U.S.C. §101.  But, the Federal Circuit’s jurisprudence in this area of the law has not been the court’s finest hour, either.  For example, while McRo v. Bandai was a good start, the Federal Circuit has been hesitant to address the role of facts/evidence in a patent eligibility analysis, in several ways.

As an aside, I made the mistake of working on this post while watching a video of Allen Iverson’s famous “Practice” press conference.  Now every time that I think about these issues, I envision Allen Iverson sitting at the dais dressed in a black robe and my mind substitutes “evidence” for “practice” and “patent eligibility” for “game”:

Some of the ways that the Federal Circuit seems hesitant to address the role of facts/evidence of patent eligibility in its opinions are:

1)  Acknowledging that patent eligibility is a question of law informed by underlying factual findings

While patent eligibility is a question of law, Federal Circuit opinions rarely recognize that previous CAFC panels have stated that there are underlying factual issues that can inform the analysis:

Whether a claim is directed to statutory subject matter is a question of law. Although determination of this question may require findings of underlying facts specific to the particular subject matter and its mode of claiming . . . .

Arrhythmia Research Technology v. Corazonix Corp., 958 F.2d 1053 (Fed. Cir. 1992).

It is well-established that “whether the asserted claims … are invalid for failure to claim statutory subject matter under 35 U.S.C. § 101, is a question of law which we review without deference.” AT & T Corp. v. Excel Commc’ns, Inc., 172 F.3d 1352, 1355 (Fed.Cir.1999). As a question of law, lack of statutory subject matter is a “ground [for affirmance] within the power of the appellate court to formulate.” Chenery, 318 U.S. at 88, 63 S.Ct. 454. While there may be cases in which the legal question as to patentable subject matter may turn on subsidiary factual issues, Comiskey has not identified any relevant fact issues that must be resolved in order to address the patentability of the subject matter of Comiskey’s application. Moreover, since we would review a Board decision on the issue of patentability without deference, see AT & T, 172 F.3d at 1355, the legal issue concerning patentability is not “a determination of policy or judgment which the agency alone is authorized to make.” Chenery, 318 U.S. at 88, 63 S.Ct. 454.

In re Comiskey, 554 F.3d 967 (Fed. Cir. 2009)(Judge Dyk writing for the court).

To their credit, many district court judges have not been shy to cite precedent that stand for the proposition that §101 is an issue of law informed by underlying factual issues.  See, e.g., SINCLAIR-ALLISON, INC. v. FIFTH AVENUE PHYSICIAN SERVICES, LLC, No. CIV-12-360-M (W.D. Okla. Dec. 19, 2012); PROTOSTORM, LLC v. ANTONELLI, TERRY, STOUT & KRAUS, LLP, No. 08-CV-931 (PKC)(JO) (E.D.N.Y. June 5, 2015); WIRELESS MEDIA INNOVATIONS, LLC v. MAHER TERMINALS, LLC, Civil Action No. 14-7004 (D.N.Y. Apr. 20, 2015); EXECWARE, LLC v. BJ’S WHOLESALE CLUB, INC., Civil Action No. 14-233-LPS (D. Del. July 15, 2015); TRIPLAY, INC. v. WhatsAPP INC., Civil Action No. 13-1703-LPS (D. Del. Apr. 28, 2015); VS TECHNOLOGIES, LLC v. TWITTER, INC., Civil Action No. 2: 11cv43 (E.D. Va. Apr. 26, 2012); Cyberfone Systems, LLC v. Cellco Partnership, 885 F. Supp. 2d 710 (D. Del. 2012).

2)  Identification of an abstract idea.

Despite the Supreme Court pointing to factual sources to support its conclusions that the claims in Bilski1 and Alice2 were directed to abstract ideas and that Mayo3 was directed to a natural phenomenon, the Federal Circuit has yet to confirm that a tribunal must always support an assertion of an abstract idea with factual evidence.

To its credit, the PTAB required such evidence in  PNC Bank v. Secure Axcess, CBM2014-0100 (PTAB Sept. 9, 2014). And, the PTAB noted that the Supreme Court supported its determination in the Alice decision:

“We also find that Petitioner does not provide sufficient persuasive evidentiary support that the placing of a trusted stamp or seal on a document is “a fundamental economic practice” or a “building block of the modern economy.” See Alice, 134 S. Ct. at 2356 (citing various references concerning the concept of intermediated settlement, including an 1896 reference).”

PNC Bank v. Secure Axcess, CBM2014-0100 (PTAB Sept. 9, 2014).

This issue was before the court, for example, in IN RE VILLENA, No. 2016-1062 (Fed. Cir. Oct. 13, 2016).  However, the court chose to decide that case by a Rule 36 Judgment;

3)  Proof of (i) conventional, (ii) routine, and (3) well-understood activity in the “significantly more” analysis

The Federal Circuit has yet to confirm that factual evidence must be provided in order to prove that an ordered combination of claim elements is a (i) conventional, (ii) routine, and (iii) well-understood activity.  At least this issue is on the radar screen of some of the judges.  For example, in the oral argument of Apple v. Ameranth, Judges Reyna and Chen inquired about this type of inquiry.  [Listen] and [Listen].  And, the USPTO Solicitor’s Office addressed the impact of a lack of evidence, as well: [Listen].  In IPLearn v. Microsoft, Judge Moore asked about evidence of conventionality: [Listen]. Unfortunately, the court issued a Rule 36 Judgment in that case.

The question of whether the “significantly more” inquiry — under step 2A of the Alice/Mayo test – is an “issue of law” or an “issue of fact” was before the Federal Circuit in January 2017 in America’s Collectibles Network v. The Jewelry Channel, Inc. USA.  In this sound bite, you can listen to the appellant clearly tee up the issue for the Federal Circuit. [Listen] The court issued a Rule 36 Judgment, however.

Similarly, in In re Villena, Judge Taranto asked whether the inquiry into whether something is “conventional” could be anything other than a fact question: [Listen].  Unfortunately, the court issued a Rule 36 Judgment.

4)  Secondary indicia of patent eligibility

Despite the opportunities to do so, the Federal Circuit has yet to recognize a principle of “secondary indicia of patent-eligibility.”  Just as evidence of “secondary indicia of non-obviousness” can be used in a 35 U.S.C. §103 analysis, evidence of “secondary indicia of patent eligibility” should be permitted in a 35 U.S.C. §101 analysis.  For example, if there is a nexus between a claimed invention and the claimed invention’s significant commercial success, it must not have been a (i) conventional, (ii) routine, and (iii) well-understood activity.  If the Supreme Court is going to conflate §§101 and 103, then secondary indicia principles under §103 should be infused into the §101 analysis, as well.

This is an issue that has been raised in several oral arguments.  For example, it was raised in Lending Tree v. Zillow : [Listen].  And, Judges Chen and Stoll observed that the argument had been made in Apple v. Ameranth: [Listen] and [Listen].  To its credit, the USPTO Solicitor’s Office even acknowledged in the oral argument of Apple v. Ameranth that secondary indicia should be considered as long as there is a nexus between the proffered secondary indicia and the claim elements: [Listen].

5)  Standard of proof to establish patent ineligibility

The Federal Circuit recently passed up the opportunity to rule that the standard of proof required to establish patent ineligibility must be by “clear and convincing evidence.”  See TRADING TECHNOLOGIES INTERNATIONAL, INC. v. CQG, INC., No. 2016-1616 (Fed. Cir. Jan. 18, 2017), at footnote 2:

2.  The parties dispute whether the district court erred in requiring proof of ineligibility under § 101 by clear and convincing evidence. Because our review is de novo, and because under either standard the legal requirements for patentability are satisfied, we need not address this dispute.

TRADING TECHNOLOGIES INTERNATIONAL, INC. v. CQG, INC., No. 2016-1616 (Fed. Cir. Jan. 18, 2017).

—————————————————————————————————————————————

1.  In Bilski v. Kappos, the Supreme Court noted:  ”In light of these precedents, it is clear that petitioners’ application is not a patentable “process.” Claims 1 and 4 in petitioners’ application explain the basic concept of hedging, or protecting against risk: “Hedging is a fundamental economic practice long prevalent in our system of commerce and taught in any introductory finance class.” 545 F.3d, at 1013 (Rader, J., dissenting); see, e.g., D. Chorafas, Introduction to Derivative Financial Instruments 75-94 (2008); C. Stickney, R. Weil, K. Schipper, & J. Francis, Financial Accounting: An Introduction to Concepts, Methods, and Uses 581-582 (13th ed.2010); S. Ross, R. Westerfield, & B. Jordan, Fundamentals of Corporate Finance 743-744 (8th ed.2008). “ Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010).

2.  In Alice v. CLS, the Supreme Court noted:  ”On their face, the claims before us are drawn to the concept of intermediated settlement, i.e., the use of a third party to mitigate settlement risk. Like the risk hedging in Bilski, the concept of intermediated settlement is “`a fundamental economic practice long prevalent in our system of commerce.’” Ibid.; see, e.g.,Emery, Speculation on the Stock and Produce Exchanges of the United States, in 7 Studies in History, Economics and Public Law 283, 346-356 (1896) (discussing the use of a “clearing-house” as an intermediary to reduce settlement risk). The use of a third-party intermediary (or “clearing house”) is also a building block of the modern economy. See, e.g., Yadav, The Problematic Case of Clearinghouses in Complex Markets, 101 Geo. L.J. 387, 406-412 (2013); J. Hull, Risk Management and Financial Institutions 103-104 (3d ed. 2012). Thus, intermediated settlement, like hedging, is an “abstract idea” beyond the scope of § 101. ”  Alice Corp. Pty. Ltd. v. CLS Bank Intern., 134 S. Ct. 2347, 2356 (2014).

3.  In Mayo Collaborative v. Prometheus Labs., 132 S. Ct. 1289, 1295 (2012), the Supreme Court observed the factual findings in the patentee’s own patent:

The patent claims at issue here set forth processes embodying researchers’ findings that identified these correlations with some precision.

More specifically, the patents—U.S. Patent No. 6,355,623 (623 patent) and U.S. Patent No. 6,680,302 (302 patent)—embody findings that concentrations in a patient’s blood of 6-TG or of 6-MMP metabolite beyond a certain level (400 and 7000 picomoles per 8×108 red blood cells, respectively) indicate that the dosage is likely too high for the patient, while concentrations in the blood of 6-TG metabolite lower than a certain level (about 230 picomoles per 8×108 red blood cells) indicate that the dosage is likely too low to be effective.

Mayo Collaborative v. Prometheus Labs., 132 S. Ct. 1289, 1295 (2012).

To the extent that the use of these factual observations in Bilski, Mayo, and Alice was mere dicta by the Supreme Court in interpreting its prior decisions, the Federal Circuit noted In Insurance Co. of the West v. US, 243 F.3d 1367, 1372 (Fed. Cir. 2001) that the Federal Circuit is obligated to follow dicta of the Supreme Court in its interpretation of prior cases:

This court is obligated to follow the Supreme Court’s interpretation in Blue Fox of those three cases, even though that interpretation may be dicta. See Stone Container Corp. v. United States, 229 F.3d 1345, 1349-50 (Fed.Cir.2000).

Insurance Co. of the West v. US, 243 F.3d 1367, 1372 (Fed. Cir. 2001).

Decision Envy

February 26th, 2017

There was a funny sound bite from back in June, shortly after the Enfish decision had been issued.  Judge Lourie initially noted that everybody cites Enfish in 101 proceedings.  Judge Chen quipped “not so much attention to DDR Holdings though” — Judge Chen authored DDR Holdings for the court.  [Listen].

Ex Parte Schulhauser

February 23rd, 2017

The IPO has scheduled for March 1, 2017 what looks to be an interesting seminar on the PTAB’s recent precedential decision in Ex Parte Schulhauser:  [Link]

Here is a list of the PTAB’s precedential decisions listed on their web page as of February 23, 2017:

Video of Ninth Circuit Oral Argument in SEAL SHIELD, LLC v. OTTER PRODUCTS, LLC

February 17th, 2017

The Ninth Circuit has close to 3,500 oral arguments on video these days.  Below is a video of a recent oral argument in a trademark dispute:

The Ninth Circuit opinion is available [here].